LPA3-mediated lysophosphatidic acid signalling in embryo implantation and spacing

Abstract
The molecular mechanisms affecting female reproduction, particularly therapeutically tractable ones, are incompletely understood. So the identification of a new signalling mechanism affecting fertility via embryo implantation could be important. The compound involved is lysophosphatidic acid (LPA), acting through a G protein-coupled receptor. Targeted deletion of the receptor, called LPA3, produces mice that display delayed implantation, altered implantation spacing, hypertrophic placentas and embryonic death. G protein-coupled receptors are among the most common targets of drug action, raising the possibility of developing new medicines for the treatment of infertility by targeting the LPA3 receptor. Every successful pregnancy requires proper embryo implantation. Low implantation rate is a major problem during infertility treatments using assisted reproductive technologies1. Here we report a newly discovered molecular influence on implantation through the lysophosphatidic acid (LPA) receptor LPA3 (refs 2–4). Targeted deletion of LPA3 in mice resulted in significantly reduced litter size, which could be attributed to delayed implantation and altered embryo spacing. These two events led to delayed embryonic development, hypertrophic placentas shared by multiple embryos and embryonic death. An enzyme demonstrated to influence implantation, cyclooxygenase 2 (COX2) (ref. 5), was downregulated in LPA3-deficient uteri during pre-implantation. Downregulation of COX2 led to reduced levels of prostaglandins E2 and I2 (PGE2 and PGI2), which are critical for implantation1. Exogenous administration of PGE2 or carbaprostacyclin (a stable analogue of PGI2) into LPA3-deficient female mice rescued delayed implantation but did not rescue defects in embryo spacing. These data identify LPA3 receptor-mediated signalling as having an influence on implantation, and further indicate linkage between LPA signalling and prostaglandin biosynthesis.